Harrison.ai vs SigTuple

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Harrison.ai employs 100-500 people, while SigTuple has 100-500 employees.

Harrison.ai has raised more in total funding at $129M, compared to SigTuple's $20M — a gap of $109M.

Harrison.ai holds the higher Awaira Score at 68/100, compared to SigTuple's 60/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 8-point gap that reflects meaningful differences in scale or traction.

Harrison.ai was founded by Aengus Tran in 2018. SigTuple was founded by Rohit Kumar Pandey in 2015. Visit each company's profile on Awaira for a full founder biography.

Harrison.ai: Harrison.ai develops AI radiology and pathology analysis software for clinical deployment, building FDA-cleared and TGA-registered algorithms for chest X-ray abnormality detection, CT pulmonary angiography analysis, and mammography screening under its Annalise.ai product brand. The Sydney company focuses on AI clinical decision support that helps radiologists prioritise worklists, detect abnormalities, and reduce reporting errors in high-volume radiology departments.\n\nThe company raised approximately $129 million including a Series C from investors including Blackbird Ventures, Skip Capital, and Telstra Ventures. Harrison.ai has deployed its Annalise.ai platform across Australian hospital networks and has received US FDA clearance for its chest X-ray AI product, enabling international commercial expansion beyond Australia. The company has published clinical validation studies demonstrating AI performance that is non-inferior to specialist radiologist reads on chest X-ray abnormality detection across multiple institutions.\n\nHarrison.ai competes in the AI radiology market against Aidoc, Lunit, Qure.ai, and Behold.ai, which all target radiologist workflow assistance and clinical alerting. The Australian healthcare market provides a strong home base given the National Health Service framework and centrally coordinated radiology procurement, while FDA clearance opens the substantially larger US radiology AI market. The company is considered one of Australia most promising medical AI companies and a flagship for the Australian healthcare technology ecosystem. SigTuple: SigTuple develops AI-powered automated pathology solutions that digitize and analyze microscopy slides for blood, urine, sputum, and semen samples, enabling high-throughput diagnostic testing without the constant presence of trained pathologists. The company's AI-Minth platform uses robotic sample preparation, high-resolution imaging, and deep learning analysis to deliver diagnostic-grade results.\n\nThe company raised approximately $20M in Series B funding and has deployed its automated microscopy systems at diagnostic labs, hospitals, and blood banks across India, processing millions of diagnostic samples. SigTuple has received regulatory approvals for its diagnostic AI products and has established partnerships with major diagnostic laboratory chains.\n\nIndia faces a severe shortage of qualified pathologists relative to population, creating an acute need for AI-assisted diagnostic automation. SigTuple's approach of combining hardware, robotics, and AI in an integrated system addresses the complete diagnostic workflow rather than just the software layer, creating higher deployment barriers but also higher switching costs and stronger network effects from accumulated diagnostic data.

SigTuple was founded first in 2015, giving it 3 years of additional market experience. Harrison.ai was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Both Harrison.ai and SigTuple report similar employee counts of approximately 100-500. Team size is often a proxy for operational scale, though lean AI companies can punch well above their headcount.

Yes, Harrison.ai and SigTuple are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.